Advertisement

Clinical Scenario: Large Volume, Non-metastatic T2 Bladder Tumor

72-year-old man with a bulky, although mobile T2 urothelial carcinoma without evidence of metastasis
  • Chad R. RitchEmail author
  • Michael S. Cookson
Chapter

Abstract

The optimal treatment of bulky, non-metastatic, and locally advanced muscle-invasive bladder cancer (MIBC) involves a combination of chemotherapy and radical cystectomy. Evidence exists to support the use of neoadjuvant chemotherapy in the treatment of MIBC; however, there are a number of scenarios where this approach is not feasible or may not be practical. The goal of this chapter is to describe our approach to the treatment of MIBC, in particular the timing and use of chemotherapy with radical cystectomy, and to provide a practical guide based on our clinical experience.

Keywords

Muscle-invasive bladder cancer Neoadjuvant chemotherapy Adjuvant chemotherapy Radical cystectomy 

Abbreviations

AC

Adjuvant chemotherapy

CR

Complete response

ECOG

Eastern Cooperative Oncology Group

GC

Gemcitabine cisplatin

MIBC

Muscle-invasive bladder cancer

M-VAC

Methotrexate vinblastine, adriamycin, cisplatin

NAC

Neoadjuvant chemotherapy

PS

Performance status

RC

Radical cystectomy

TURBT

Transurethral resection of the bladder

References

  1. 1.
    Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013;63(1):58–66. Epub 2012/08/25.PubMedCrossRefGoogle Scholar
  2. 2.
    Porter MP, Kerrigan MC, Donato BM, Ramsey SD. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol. 2011;29(3):252–8. Epub 2009/05/20.PubMedCrossRefGoogle Scholar
  3. 3.
    Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66. Epub 2003/08/29.PubMedCrossRefGoogle Scholar
  4. 4.
    von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068–77. Epub 2000/09/23.PubMedGoogle Scholar
  5. 5.
    Dash A, Pettus JA, Herr HW, Bochner BH, Dalbagni G, Donat SM, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer. 2008;113(9):2471–7. Epub 2008/10/01.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Raghavan D, Burgess E, Gaston KE, Haake MR, Riggs SB. Neoadjuvant and adjuvant chemotherapy approaches for invasive bladder cancer. Semin Oncol. 2012;39(5):588–97. Epub 2012/10/09.PubMedCrossRefGoogle Scholar
  7. 7.
    Smith DC, Mackler NJ, Dunn RL, Hussain M, Wood D, Lee CT, et al. Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. J Urol. 2008;180(6):2384–8. discussion 8. Epub 2008/10/22.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Dogliotti L, Carteni G, Siena S, Bertetto O, Martoni A, Bono A, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007;52(1):134–41. Epub 2007/01/09.PubMedCrossRefGoogle Scholar
  9. 9.
    Gregg JR, Cookson MS, Phillips S, Salem S, Chang SS, Clark PE, et al. Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. J Urol. 2011;185(1):90–6. Epub 2010/11/16.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Scher HI, Yagoda A, Herr HW, Sternberg CN, Bosl G, Morse MJ, et al. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol. 1988;139(3):470–4. Epub 1988/03/01.PubMedGoogle Scholar
  11. 11.
    Apolo AB, Grossman HB, Bajorin D, Steinberg G, Kamat AM. Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting. Urol Oncol. 2012;30(6):772–80. Epub 2012/12/12.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Eldefrawy A, Soloway MS, Katkoori D, Singal R, Pan D, Manoharan M. Neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer: The likelihood of initiation and completion. Indian J Urol. 2012;28(4):424–6. Epub 2013/03/02.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Advanced Bladder Cancer Meta-analysis C. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol. 2005;48(2):189–99; discussion 99–201. Epub 2005/06/09.Google Scholar
  14. 14.
    Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009;55(1):164–74. Epub 2008/08/05.PubMedCrossRefGoogle Scholar
  15. 15.
    Stimson CJ, Chang SS, Barocas DA, Humphrey JE, Patel SG, Clark PE, et al. Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J Urol. 2010;184(4):1296–300. Epub 2010/08/21.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Miller School of MedicineUniversity of MiamiMiamiUSA
  2. 2.University of Oklahoma Medical CenterOklahoma CityUSA

Personalised recommendations